Document Detail


Early Intensification Treatment Approach in Advanced-stage Hodgkin Lymphoma.
MedLine Citation:
PMID:  24287068     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The key question in advanced-stage Hodgkin lymphoma for many years now has been, should intensified chemotherapy be applied upfront or be reserved for relapsing patients. The early intensification approach with BEACOPPescalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) aims at curing patients with first-line chemotherapy definitely. The added toxicity of this approach as compared to less intensive regimens as ABDV (doxorubicin, bleomycin, dacarbazine, vinblastine) is mainly restricted to acute haematotoxicity and gonadal damage. However, regarding efficacy, there is a meaningful survival-benefit over ABVD (10% at 5years) and the intensified first-line treatment strategy is thus rightly regarded as standard of care.
Authors:
Peter Borchmann
Related Documents :
10225548 - Effectiveness of a sanguinarine regimen after scaling and root planing.
15648398 - The pathophysiology of treatment-related nausea and vomiting in cancer patients: curren...
23472708 - Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas.
24048758 - Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
11878578 - Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-g...
16761928 - Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hematology/oncology clinics of North America     Volume:  28     ISSN:  1558-1977     ISO Abbreviation:  Hematol. Oncol. Clin. North Am.     Publication Date:  2014 Feb 
Date Detail:
Created Date:  2013-11-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709473     Medline TA:  Hematol Oncol Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  65-74     Citation Subset:  IM    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Affiliation:
1st Department of Internal Medicine, German Hodgkin Study Group, University Hospital Cologne, Kerpener Straße 62, 50924 Koeln, Germany. Electronic address: peter.borchmann@uni-koeln.de.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Balancing risks and benefits of therapy for patients with favorable-risk limited-stage hodgkin lymph...
Next Document:  Induction Therapy for Advanced-stage Hodgkin Lymphoma: Late Intensification (ABVD Chemotherapy Follo...